Nurse Practitioner Program year 2025 Reported 2022–2025 Source: CMS Open Payments, 2026 publication

Beth Wagner

Nurse Practitioner Wyomissing, PA Nurse Practitioner

NPI 1205440138 CMS profile 11311553

2608 Keiser Blvd, Wyomissing, PA 19610

Open in the dashboard

General payments

$8,555

354 records reported · program years 2022–2025

Research payments

$0

Paid to them · None reported · program years 2022–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Beth Wagner of Wyomissing, PA is reported in the CMS Open Payments database as having received $8,555 across 354 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,693 133
2024 General $2,288 99
2023 General $1,862 82
2022 General $713 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Beth Wagner
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Beth Wagner were reported at $3,693. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Beth Wagner Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $0 $135 $40–$426 $132
2022 $713 $152 $48–$470 $149
2023 $1,862 $166 $54–$529 $160
2024 $2,288 $173 $55–$556 $164
2025 $3,693 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2022–2025
  1. GlaxoSmithKline, LLC. $1,196 67 payments
  2. Inspire Medical Systems, Inc. $835 12 payments
  3. Harmony Biosciences LLC $770 38 payments
  4. Regeneron Healthcare Solutions, Inc. $726 26 payments
  5. Genzyme Corporation $601 26 payments
  6. AstraZeneca Pharmaceuticals LP $601 9 payments
  7. Jazz Pharmaceuticals Inc. $477 11 payments
  8. Insmed, Inc. $446 23 payments
  9. Grifols USA, LLC $387 19 payments
  10. Mylan Specialty L.P. $286 15 payments
  11. Other $2,231 108 payments

Every payment, record by record

What the payments were for General payments · program years 2022–2025
  1. Food and Beverage $7,921 349 payments
  2. Travel and Lodging $361 2 payments
  3. Education $274 3 payments
Products named General payments · program years 2022–2025
  1. INSPIRE $835 12 payments
  2. TRELEGY ELLIPTA $655 36 payments
  3. DUPIXENT Immunology $576 25 payments
  4. DUPIXENT Inflammation And Immunology $531 19 payments
  5. AIRSUPRA $531 4 payments
  6. XYWAV $477 11 payments
  7. Arikayce $446 23 payments
  8. WAKIX $442 23 payments
  9. FASENRA $441 3 payments
  10. NUCALA $416 30 payments
  11. Other $4,859 204 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 6 billing codes

Paid by Medicare

$24,133

Medicare's payments for the services billed

Medicare patients

205

Average age 70

Services billed

574

88 women, 117 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 44%
Diabetes 32%
Atrial fibrillation 28%
Ischemic heart disease 27%
Depression 23%
Chronic kidney disease 19%
Heart failure 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $280
  • GENZYME CORPORATION $141
$420 — —
NUCALA
  • GlaxoSmithKline, LLC. $189
$189 — —
WAKIX
  • Harmony Biosciences LLC $186
$186 — —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $173
$173 — —
XOLAIR
  • Novartis Pharmaceuticals Corporation $143
$143 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

354 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record